Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • Maine


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com

Portland

Lewiston

Bangor

South Portland

Auburn

Brunswick

Biddeford

Sanford

Augusta

Scarborough


Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Validation of a Shared Decision-Making Tool for Multiple Sclerosis
    NCT04122989
    Condition:   Multiple Sclerosis
    Intervention:   Other: MS-SUPPORT
    Sponsors:   Shared Decision Making Resources;   EMD Serono;   Multiple Sclerosis Association of America;   Multiple Sclerosis Alliance of Southern Colorado
    Recruiting
  • Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage
    NCT03604276
    Conditions:   Subarachnoid Hemorrhage, Aneurysmal;   Headache;   Subarachnoid Hemorrhage
    Intervention:  
    Sponsor:   Maine Medical Center
    Recruiting
  • Treatment of HFpEF With Nitrate Supplement
    NCT03289481
    Condition:   Heart Failure With Normal Ejection Fraction
    Interventions:   Dietary Supplement: Active lozenge;   Drug: Placebo
    Sponsors:   Penobscot Bay Medical Center;   HumanN
    Completed
  • Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?
    NCT03219294
    Condition:   Arthropathy of Hip
    Interventions:   Drug: Vecuronium 0.1 mg/kg;   Drug: Vecuronium 0.2mg/kg
    Sponsors:   Craig Curry;   Maine Medical Center;   Spectrum Medical Group Anesthesiology
    Completed
  • Phase 1 Study of HBN-1
    NCT04094857
    Condition:   Cardiac Arrest
    Intervention:   Drug: HBN-1
    Sponsor:   Hibernaid, Inc
    Not yet recruiting
  • Online Mindfulness-based Tic Reduction (Phase Two)
    NCT03771235
    Conditions:   Tourette Syndrome;   Persistent Tic Disorder
    Interventions:   Behavioral: Mindfulness-based Intervention for Tics;   Behavioral: Tic Information and Coping Strategies
    Sponsors:   Bowdoin College;   Massachusetts General Hospital
    Recruiting
  • Online Mindfulness-based Tic Reduction
    NCT03525626
    Conditions:   Tourette Syndrome;   Tic Disorders
    Intervention:   Behavioral: Online Mindfulness-based Tic Reduction
    Sponsors:   Bowdoin College;   Massachusetts General Hospital
    Completed
  • Prospective Clinicogenomic Program
    NCT04180176
    Conditions:   Non-Small Cell Lung Cancer (NSCLC);   Small-Cell Lung Cancer (SCLC)
    Intervention:   Other: Blood Draw
    Sponsors:   Genentech, Inc.;   Flatiron Health, Inc.; Foundation Medicine, Inc.
    Not yet recruiting
  • Study of TOP1630 for Dry Eye Syndrome
    NCT03833388
    Condition:   Dry Eye Syndrome
    Interventions:   Drug: TOP1630 0.1% Ophthalmic Solution TID OU;   Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
    Sponsor:   Topivert Pharma Ltd
    Completed
  • Amantadine to Speed Awakening After Cardiac Arrest
    NCT02486211
    Conditions:   Coma;   Heart Arrest;   Anoxia
    Interventions:   Drug: Amantadine;   Drug: Placebo
    Sponsors:   Jon Rittenberger, MD;   American Heart Association
    Completed
  • A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
    NCT04084483
    Condition:   Dry Eye Disease
    Interventions:   Drug: K-161;   Other: Placebo (Vehicle)
    Sponsor:   Kowa Research Institute, Inc.
    Recruiting
  • Cenobamate Open-Label Extension Study for YKP3089C025
    NCT03961568
    Condition:   Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
    Intervention:   Drug: Cenobamate
    Sponsor:   SK Life Science, Inc.
    Enrolling by invitation
  • CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
    NCT02617667
    Condition:   Dry Eye Syndromes
    Interventions:   Drug: Cyclosporine A;   Drug: Placebo
    Sponsor:   Novaliq GmbH
    Completed
  • Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
    NCT01234766
    Condition:   Lymphoma, Follicular
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Cephalon;   Spectrum Pharmaceuticals, Inc
    Active, not recruiting
  • Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
    NCT03737981
    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
    NCT03633331
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Promoting Informed Decisions About Cancer Screening in Older Adults
    NCT03959696
    Condition:   Colorectal Cancer Screening
    Interventions:   Behavioral: Notification;   Behavioral: Training
    Sponsors:   Massachusetts General Hospital;   Maine Medical Center;   Brigham and Women's Hospital;   Newton-Wellesley Hospital;   North Shore Medical Center
    Enrolling by invitation
  • Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
    NCT03580928
    Condition:   Chronic Lymphocytic Leukemia (CLL)
    Interventions:   Drug: Venetoclax;   Drug: Obinutuzumab;   Drug: Acalabrutinib
    Sponsors:   Dana-Farber Cancer Institute;   Acerta Pharma, LLC;   Genentech, Inc.
    Recruiting
  • A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
    NCT01960010
    Condition:   Dry Eye Syndromes
    Interventions:   Drug: MIM-D3 Ophthalmic Solution;   Drug: Vehicle
    Sponsor:   Mimetogen Pharmaceuticals USA, Inc.
    Completed
  • De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
    NCT03952585
    Conditions:   Basaloid Squamous Cell Carcinoma;   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Oropharyngeal Squamous Cell Carcinoma;   Papillary Squamous Cell Carcinoma;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Image Guided Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
    NCT03811002
    Conditions:   Limited Stage Lung Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
    NCT03775265
    Conditions:   Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall;   Bladder Urothelial Carcinoma;   Stage II Bladder Cancer AJCC v8;   Stage III Bladder Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8
    Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Mitomycin;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Other: Survey Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
    NCT03371719
    Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
    Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
    NCT03382561
    Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
    NCT03055013
    Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
    Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    NCT03092674
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
    NCT02785952
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
    NCT02595944
    Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Intervention:   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
    NCT02997228
    Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
    NCT03488693
    Condition:   Breast Cancer
    Interventions:   Radiation: Radiation;   Other: No Radiation
    Sponsors:   Canadian Cancer Trials Group;   Alliance for Clinical Trials in Oncology;   Eastern Cooperative Oncology Group;   NRG Oncology;   Southwest Oncology Group
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
    NCT02196181
    Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
    NCT02154490
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
    NCT02032823
    Condition:   Breast Cancer
    Interventions:   Drug: Olaparib;   Drug: Placebo
    Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
    Active, not recruiting
  • Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
    NCT02364557
    Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
    Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
    NCT01674140
    Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
    NCT01863550
    Condition:   Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Cardiovascular Inflammation Reduction Trial
    NCT01594333
    Condition:   Cardiovascular Disease
    Interventions:   Drug: Methotrexate;   Drug: Placebo
    Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Completed
  • Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
    NCT02115282
    Conditions:   Breast Adenocarcinoma;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
    NCT02019264
    Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
    Interventions:   Drug: Lorcaserin hydrochloride;   Drug: Placebo
    Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
    Completed
  • Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
    NCT01901094
    Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Suspended
  • Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
    NCT01272037
    Conditions:   Ductal Breast Carcinoma In Situ;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
    NCT03367702
    Condition:   Stage II Prostate Adenocarcinoma
    Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
    NCT03180268
    Conditions:   Grade II Meningioma;   Intracranial Meningioma
    Interventions:   Other: Clinical Observation;   Radiation: Radiation Therapy
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction
    NCT02929329
    Condition:   Heart Failure
    Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
    Sponsors:   Amgen;   Cytokinetics;   Servier
    Active, not recruiting
  • FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
    NCT02890355
    Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
    Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
    NCT02595905
    Conditions:   Breast Carcinoma Metastatic in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
    NCT02506153
    Conditions:   Metastatic Cutaneous Melanoma;   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
    Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    NCT00310180
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
    Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
    Active, not recruiting
  • Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    NCT02152982
    Conditions:   Glioblastoma;   Gliosarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    NCT02048813
    Conditions:   Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
    NCT02004275
    Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
    NCT01953588
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: fulvestrant;   Drug: anastrozole
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
    NCT00769379
    Condition:   Ductal Breast Carcinoma In Situ
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
    NCT01950390
    Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
    NCT01903811
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
    NCT01764633
    Condition:   Dyslipidemia
    Interventions:   Biological: Evolocumab;   Drug: Placebo
    Sponsor:   Amgen
    Completed
  • Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
    NCT01575548
    Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v7
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive and High-Risk, Lymph Node-Negative Breast Cancer
    NCT00433511
    Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   ECOG-ACRIN Cancer Research Group;   North Central Cancer Treatment Group
    Active, not recruiting
  • Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    NCT01169337
    Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Other: Clinical Observation;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
    NCT00878709
    Condition:   Breast Cancer
    Interventions:   Drug: neratinib;   Other: placebo
    Sponsor:   Puma Biotechnology, Inc.
    Active, not recruiting
  • Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
    NCT00785291
    Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Biological: Bevacizumab;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
    NCT03984448
    Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
    NCT03788746
    Condition:   Urothelial Carcinoma
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting
  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
    NCT03678025
    Conditions:   Castration Levels of Testosterone;   Metastatic Prostatic Adenocarcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Drug: Abiraterone;   Drug: Bicalutamide;   Drug: Degarelix;   Drug: Docetaxel;   Drug: Flutamide;   Drug: Goserelin Acetate;   Drug: Histrelin Acetate;   Drug: Leuprolide Acetate;   Drug: Nilutamide;   Procedure: Orchiectomy;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Radical Prostatectomy;   Drug: Triptorelin
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
    NCT00217737
    Conditions:   Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer AJCC v7;   Stage IIB Colon Cancer AJCC v7;   Stage IIC Colon Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer
    NCT03660826
    Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
    NCT03199885
    Conditions:   Breast Adenocarcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
    NCT03155997
    Condition:   Breast Cancer
    Interventions:   Drug: Abemaciclib;   Drug: Standard Adjuvant Endocrine Therapy
    Sponsors:   Eli Lilly and Company;   NSABP Foundation Inc
    Active, not recruiting
  • Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
    NCT02926911
    Conditions:   DCIS;   Ductal Carcinoma in Situ
    Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
    Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
    Recruiting
  • Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
    NCT02867813
    Condition:   Dyslipidemia
    Intervention:   Biological: Evolocumab
    Sponsor:   Amgen
    Active, not recruiting
  • Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02839707
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
    NCT02684006
    Condition:   Renal Cell Cancer
    Interventions:   Drug: Avelumab (MSB0010718C);   Drug: Axitinib (AG-013736);   Drug: Sunitinib
    Sponsor:   Pfizer
    Active, not recruiting
  • informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
    NCT02582879
    Condition:   Chronic Lymphocytic Leukemia (CLL)
    Intervention:  
    Sponsors:   Pharmacyclics LLC.;   Janssen, LP
    Active, not recruiting
  • Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02502266
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02446600
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   AstraZeneca;   NRG Oncology
    Active, not recruiting
  • Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
    NCT02339571
    Conditions:   Recurrent Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Biological: Sargramostim
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    NCT02311933
    Conditions:   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
    NCT02164916
    Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Roche-Genentech
    Active, not recruiting
  • Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
    NCT01942135
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Palbociclib;   Drug: Fulvestrant;   Drug: Placebo
    Sponsors:   Pfizer;   AstraZeneca
    Active, not recruiting
  • Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
    NCT01856192
    Conditions:   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
    NCT01835158
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Kidney Carcinoma;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
    NCT01415752
    Conditions:   Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
    Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
    NCT01286272
    Conditions:   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma;   Grade 3a Follicular Lymphoma
    Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Bortezomib;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Biological: Ofatumumab;   Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
    NCT01196390
    Conditions:   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Stage IB Esophageal Cancer AJCC v7;   Stage IIA Esophageal Cancer AJCC v7;   Stage IIB Esophageal Cancer AJCC v7;   Stage IIIA Esophageal Cancer AJCC v7;   Stage IIIB Esophageal Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    NCT00951496
    Conditions:   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Carcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    NCT00942331
    Conditions:   Advanced Urothelial Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Prostate Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Unresectable Urothelial Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
    NCT00844649
    Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: Albumin-bound paclitaxel (ABI-007);   Drug: Gemcitabine
    Sponsor:   Celgene
    Completed
  • Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
    NCT00644228
    Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
    NCT00601900
    Conditions:   Invasive Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Questionnaire Administration;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
    NCT03244826
    Condition:   Other Cancer
    Interventions:   Other: Shared Care;   Other: Standard Care
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting
  • Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer
    NCT04095364
    Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
    NCT04094688
    Condition:   Colorectal Adenocarcinoma
    Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
    NCT03088813
    Condition:   Small Cell Lung Cancer
    Interventions:   Drug: Irinotecan liposome injection;   Drug: Topotecan
    Sponsor:   Ipsen
    Recruiting
  • A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
    NCT03988114
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI)
    Sponsor:   Eli Lilly and Company
    Withdrawn
  • Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
    NCT03914612
    Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Dedifferentiated Carcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Endometrial Clear Cell Adenocarcinoma;   Recurrent Endometrial Dedifferentiated Carcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Mixed Cell Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Endometrial Undifferentiated Carcinoma;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
    NCT03757949
    Condition:   Bladder Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Nutritional Intervention;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
    NCT03737994
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
    NCT03422003
    Condition:   Breast Cancer
    Intervention:   Radiation: Radiation Therapy
    Sponsors:   Dana-Farber Cancer Institute;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
    NCT03701308
    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Uproleselan
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
    NCT03456830
    Condition:   Enteric Hyperoxaluria
    Interventions:   Drug: ALLN-177;   Drug: Placebo
    Sponsor:   Allena Pharmaceuticals
    Active, not recruiting
  • Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
    NCT03348631
    Conditions:   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Clear Cell Adenocarcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
    NCT03274687
    Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
    Interventions:   Radiation: Hypofractionated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
    NCT02921256
    Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
    NCT02856581
    Condition:   Lung Carcinoma
    Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
    Active, not recruiting
  • Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
    NCT02836873
    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Bexagliflozin;   Drug: Placebo
    Sponsor:   Theracos
    Completed
  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
    NCT02783573
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Lanabecestat;   Drug: Placebo
    Sponsors:   AstraZeneca;   Eli Lilly and Company
    Terminated
  • CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
    NCT02670083
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Crenezumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Completed
  • Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
    NCT02554890
    Condition:   Acute Heart Failure
    Interventions:   Drug: sacubitril/valsartan (LCZ696);   Drug: Enalapril;   Drug: sacubitril/valsartan (LCZ696) matching placebo;   Drug: enalapril matching placebo
    Sponsor:   Novartis Pharmaceuticals
    Completed
  • Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
    NCT02547818
    Condition:   Alzheimer's Disease
    Interventions:   Drug: ALZT-OP1a;   Drug: ALZT-OP1b;   Other: Placebo ALZT-OP1a;   Other: Placebo ALZT-OP1b
    Sponsors:   AZTherapies, Inc.;   PharmaConsulting Group;   KCAS Bio;   APCER Life Sciences
    Active, not recruiting
  • PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
    NCT02513394
    Condition:   Breast Cancer
    Interventions:   Drug: Palbociclib;   Drug: Standard Adjuvant Endocrine Therapy
    Sponsors:   Alliance Foundation Trials, LLC.;   Austrian Breast & Colorectal Cancer Study Group;   NSABP Foundation Inc;   PrECOG, LLC.;   Breast International Group;   Pfizer
    Active, not recruiting
  • A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
    NCT02451137
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Insulin glargine, 300 U/ml;   Drug: Insulin glargine, 100 U/ml;   Drug: Insulin detemir;   Drug: Background Therapy
    Sponsor:   Sanofi
    Completed
  • Absorb IV Randomized Controlled Trial
    NCT02173379
    Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
    Interventions:   Device: Absorb BVS;   Device: XIENCE
    Sponsor:   Abbott Medical Devices
    Active, not recruiting
  • Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
    NCT02065791
    Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
    Interventions:   Drug: Canagliflozin;   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
    Completed
  • Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
    NCT02027428
    Condition:   Squamous Cell Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
    Sponsor:   Celgene
    Completed
  • Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
    NCT02003222
    Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Active, not recruiting
  • Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
    NCT02003209
    Conditions:   HER2/Neu Positive;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
    Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Other: Cytology Specimen Collection Procedure;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
    NCT01920711
    Condition:   Heart Failure With Preserved Ejection Fraction
    Interventions:   Drug: LCZ696;   Drug: Valsartan
    Sponsor:   Novartis Pharmaceuticals
    Completed
  • Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
    NCT01900665
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Solanezumab;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Terminated
  • Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    NCT01872975
    Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
    NCT01822509
    Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Myeloproliferative Neoplasm;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hematologic Malignancy;   Recurrent Hodgkin Lymphoma;   Recurrent Myelodysplastic Syndrome;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
    NCT01822496
    Conditions:   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Radiation: Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib;   Drug: Etoposide;   Drug: Paclitaxel
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Terminated
  • A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
    NCT01772472
    Condition:   Breast Cancer
    Interventions:   Drug: trastuzumab;   Drug: trastuzumab emtansine
    Sponsors:   Hoffmann-La Roche;   NSABP Foundation Inc;   German Breast Group
    Active, not recruiting
  • ABSORB III Randomized Controlled Trial (RCT)
    NCT01751906
    Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
    Interventions:   Device: Absorb BVS;   Device: XIENCE
    Sponsor:   Abbott Medical Devices
    Completed
  • A Study of Evacetrapib in High-Risk Vascular Disease
    NCT01687998
    Condition:   Cardiovascular Diseases
    Interventions:   Drug: Evacetrapib;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
    Terminated
  • Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
    NCT01573442
    Conditions:   Arthralgia;   Breast Cancer;   Hot Flashes;   Musculoskeletal Complications;   Sexual Dysfunction
    Interventions:   Drug: testosterone;   Other: placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Completed
  • Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
    NCT01535053
    Conditions:   Choriocarcinoma;   FIGO Stage I Gestational Trophoblastic Tumor;   FIGO Stage II Gestational Trophoblastic Tumor;   FIGO Stage III Gestational Trophoblastic Tumor;   Hydatidiform Mole
    Interventions:   Biological: Dactinomycin;   Drug: Leucovorin Calcium;   Drug: Methotrexate;   Other: Quality-of-Life Assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
    NCT01498289
    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
    Interventions:   Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Open Label Study of Long Term Evaluation Against LDL-C Trial
    NCT01439880
    Condition:   Hypercholesterolemia
    Interventions:   Biological: Evolocumab;   Other: Standard of care
    Sponsor:   Amgen
    Completed
  • Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
    NCT01420926
    Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
    NCT01358877
    Condition:   Breast Cancer
    Interventions:   Drug: 5-Fluorouracil;   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Epirubicin;   Drug: Paclitaxel;   Drug: Pertuzumab;   Drug: Placebo;   Drug: Trastuzumab
    Sponsors:   Hoffmann-La Roche;   Genentech, Inc.;   Breast International Group
    Active, not recruiting
  • Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
    NCT01256398
    Conditions:   Acute Lymphoblastic Leukemia;   Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    Interventions:   Biological: Alemtuzumab;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide Phosphate;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Melphalan;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Tacrolimus;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
    NCT01253070
    Conditions:   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Acute Promyelocytic Leukemia With PML-RARA;   FLT3 Gene Mutation;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Biopsy;   Procedure: Bone Marrow Aspiration;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
    NCT01238211
    Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Core Binding Factor Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    NCT01167712
    Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Procedure: Computed Tomography;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
    NCT01145495
    Conditions:   Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • PRE-DETERMINE Cohort Study
    NCT01114269
    Conditions:   Coronary Artery Disease;   Left Ventricular Dysfunction;   Sudden Cardiac Death
    Intervention:  
    Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Abbott Medical Devices;   Northwestern University;   Roche Diagnostics;   Quintiles, Inc.
    Active, not recruiting
  • Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
    NCT00892177
    Condition:   Glioblastoma Multiforme
    Interventions:   Biological: bevacizumab;   Drug: dasatinib;   Other: placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Completed
  • Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
    NCT00887146
    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
    Recruiting
  • Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
    NCT00884741
    Conditions:   Glioblastoma;   Gliosarcoma;   Supratentorial Glioblastoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Biological: Bevacizumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   NRG Oncology
    Completed
  • Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
    NCT00770809
    Conditions:   Male Breast Carcinoma;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    NCT00588770
    Conditions:   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Major Salivary Gland Cancer AJCC v7;   Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Laryngeal Verrucous Carcinoma AJCC v7;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Major Salivary Gland Cancer AJCC v7;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVA Oral Cavity Cancer AJCC v6 and v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Laryngeal Verrucous Carcinoma AJCC v7;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Major Salivary Gland Cancer AJCC v7;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVB Oral Cavity Cancer AJCC v6 and v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Laryngeal Verrucous Carcinoma AJCC v7;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVC Major Salivary Gland Cancer AJCC v7;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVC Oral Cavity Cancer AJCC v6 and v7;   Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Tongue Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
    NCT00540514
    Condition:   Non-Small Cell Lung Carcinoma
    Interventions:   Drug: Albumin-bound paclitaxel;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsor:   Celgene
    Completed
  • ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
    NCT00490139
    Condition:   Neoplasms, Breast
    Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
    Sponsors:   Novartis Pharmaceuticals;   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Breast International Group;   Canadian Cancer Trials Group
    Active, not recruiting
  • Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
    NCT00443274
    Condition:   Breast Implant
    Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
    Sponsor:   Allergan
    Active, not recruiting
  • Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
    NCT00390455
    Conditions:   Estrogen Receptor Positive;   HER2 Positive Breast Carcinoma;   HER2/Neu Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
    NCT00262847
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Completed
  • Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
    NCT00262821
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
    Interventions:   Drug: cisplatin;   Drug: tirapazamine
    Sponsors:   National Cancer Institute (NCI);   NCIC Clinical Trials Group;   Gynecologic Oncology Group
    Terminated
  • Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
    NCT00070499
    Condition:   Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
    NCT00066690
    Conditions:   Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Procedure: Oophorectomy;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen;   Drug: Triptorelin
    Sponsors:   International Breast Cancer Study Group;   Breast International Group;   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
    Active, not recruiting
  • Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
    NCT00003857
    Condition:   Breast Cancer
    Interventions:   Drug: tamoxifen citrate;   Procedure: adjuvant therapy;   Radiation: radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   NRG Oncology
    Active, not recruiting
  • Symptom Management Implementation of Patient Reported Outcomes in Oncology
    NCT03850912
    Conditions:   Other Cancer;   Gastrointestinal Cancer;   Thoracic Cancer;   Gynecologic Cancer
    Interventions:   Other: eSyM App Usage;   Other: SASS Questionnaire
    Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI);   RTI International;   Baptist Memorial Health Care Corporation;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   West Virginia University;   Lifespan
    Recruiting
  • Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis
    NCT03042104
    Conditions:   Aortic Stenosis;   Heart Diseases
    Intervention:   Device: Edwards SAPIEN 3 THV
    Sponsor:   Edwards Lifesciences
    Recruiting
  • Diuretic Comparison Project
    NCT02185417
    Condition:   Hypertension
    Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Percutaneous Localization: Open-label Registry of Thoracic Surgery
    NCT04066699
    Conditions:   Lung Lesion(s) Requiring Evaluation;   Pulmonary Metastasis;   Pulmonary Nodule, Solitary;   Peripheral Lung Lesions
    Intervention:   Procedure: Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.
    Sponsor:   Veran Medical Technologies
    Recruiting
  • A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
    NCT03404115
    Condition:   Dry Eye Syndrome
    Interventions:   Drug: Reproxalap Ophthalmic Solution (0.25%);   Drug: Reproxalap Ophthalmic Solution (0.1%);   Drug: Vehicle Ophthalmic Solution
    Sponsor:   Aldeyra Therapeutics, Inc.
    Completed
  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
    NCT03907488
    Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
    NCT03377556
    Conditions:   ATM Gene Mutation;   ATR Gene Mutation;   BARD1 Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   BRIP1 Gene Mutation;   CHEK1 Gene Mutation;   CHEK2 Gene Mutation;   FANCA Gene Mutation;   FANCC Gene Mutation;   FANCD2 Gene Mutation;   FANCF Gene Mutation;   FANCM Gene Mutation;   NBN Gene Mutation;   PALB2 Gene Mutation;   RAD51 Gene Mutation;   RAD51B Gene Mutation;   RAD54L Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   RPA1 Gene Mutation;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
    NCT01274338
    Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502
    NCT03609021
    Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
    Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline
    NCT03744910
    Condition:   Antibody-mediated Rejection
    Interventions:   Biological: Clazakizumab;   Drug: Normal saline
    Sponsors:   Vitaeris INC;   ICON Clinical Research
    Recruiting
  • Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
    NCT03632135
    Condition:   Recurrent Glioblastoma
    Interventions:   Diagnostic Test: ChemoID assay;   Drug: Chemotherapy
    Sponsor:   Cordgenics, LLC
    Recruiting
  • Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
    NCT03414684
    Condition:   Breast Cancer
    Interventions:   Drug: Carboplatin;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting
  • Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
    NCT03289039
    Condition:   Breast Cancer
    Interventions:   Drug: Neratinib;   Drug: Fulvestrant
    Sponsors:   Dana-Farber Cancer Institute;   Puma Biotechnology, Inc.
    Recruiting
  • Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
    NCT01627041
    Conditions:   Acute Myeloid Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
    NCT02764541
    Condition:   Breast Cancer
    Interventions:   Drug: Letrozole;   Drug: Tamoxifen;   Drug: Palbociclib;   Drug: Endocrine Therapy
    Sponsors:   Dana-Farber Cancer Institute;   Pfizer
    Recruiting
  • Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
    NCT02441686
    Condition:   Multiple Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.;   Celgene
    Active, not recruiting
  • ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
    NCT03587740
    Condition:   Breast Cancer
    Intervention:   Drug: T-DM1
    Sponsors:   Dana-Farber Cancer Institute;   Susan G. Komen Breast Cancer Foundation;   Gateway for Cancer Research
    Recruiting
  • Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
    NCT03534323
    Conditions:   Chronic Lymphocytic Leukemia;   Richter Syndrome
    Interventions:   Drug: Duvelisib;   Drug: Venetoclax
    Sponsors:   Dana-Farber Cancer Institute;   Verastem, Inc.
    Recruiting
  • A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy
    NCT04151563
    Condition:   Carcinoma, Non-small Cell Lung
    Interventions:   Biological: nivolumab;   Biological: ipilimumab;   Drug: cabozantinib;   Drug: docetaxel;   Biological: ramucirumab;   Drug: lucitanib
    Sponsors:   Bristol-Myers Squibb;   Clovis Oncology, Inc.;   Exelixis;   Eli Lilly and Company
    Not yet recruiting
  • Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial
    NCT03855787
    Condition:   Kidney Calculi
    Intervention:   Procedure: Ureteroscopy
    Sponsors:   Vanderbilt University Medical Center;   University of Michigan;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Maine Medical Center;   Mayo Clinic;   Université de Montréal;   University of California, Davis;   University of California, San Diego;   Indiana University
    Recruiting
  • Study of SkQ1 as Treatment for Dry-eye Syndrome
    NCT03764735
    Condition:   Dry Eye Syndrome
    Interventions:   Drug: Low Dose - SkQ1;   Drug: High dose - SkQ1;   Drug: SkQ1 (Vehicle)
    Sponsors:   Mitotech, SA;   ORA, Inc.
    Completed
  • Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
    NCT03180684
    Conditions:   Vulvar High Grade Squamous Intraepithelial Lesion (HSIL);   Vulvar Dysplasia;   Vulvar Intraepithelial Neoplasia (VIN);   VIN2;   VIN3;   Pre-cancerous Lesions of the Vulva;   Human Papillomavirus (HPV)
    Interventions:   Biological: VGX-3100;   Drug: Imiquimod 5% cream;   Device: CELLECTRA™ 2000
    Sponsor:   Inovio Pharmaceuticals
    Active, not recruiting
  • A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
    NCT01602380
    Condition:   Hormone Receptor Positive Breast Cancer
    Interventions:   Drug: faslodex 500mg;   Drug: arimidex 1mg;   Drug: faslodex dummy;   Drug: arimidex dummy
    Sponsor:   AstraZeneca
    Active, not recruiting
  • Endurant Evo US Clinical Trial
    NCT02393716
    Conditions:   Abdominal Aortic Aneurysm;   AAA
    Interventions:   Device: Endurant Evo AAA Stent Graft System;   Procedure: Endovascular aneurysm repair (EVAR)
    Sponsor:   Medtronic Endovascular
    Active, not recruiting
  • Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
    NCT03180502
    Conditions:   1p/19q Co-deletion;   Anaplastic Astrocytoma;   Diffuse Astrocytoma;   Glioma;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Oligoastrocytoma;   Oligodendroglioma;   WHO Grade III Glioma
    Interventions:   Radiation: IMRT (Intensity-Modulated Radiation Therapy);   Radiation: Proton Beam Radiation Therapy;   Drug: Temozolomide
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab
    NCT04108156
    Condition:   Diabetic Macular Edema
    Interventions:   Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab;   Drug: Intravitreal Ranibizumab 0.5 mg Injection
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
    NCT04102098
    Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
    NCT04068896
    Conditions:   Pancreatic Cancer;   Metastatic Castration-resistant Prostate Cancer;   Bladder Cancer;   Melanoma;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Gastric Cancer;   Esophageal Cancer;   Ovarian Cancer;   Head Neck Squamous Cell Carcinoma
    Interventions:   Biological: NGM120;   Other: Placebo
    Sponsor:   NGM Biopharmaceuticals, Inc
    Recruiting
  • Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
    NCT04045665
    Conditions:   Atrial Fibrillation;   Stroke;   Bleeding
    Interventions:   Drug: Antiplatelet-only strategy;   Drug: Oral Anticoagulant plus background antiplatelet therapy
    Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Vanderbilt University Medical Center
    Not yet recruiting
  • A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
    NCT04031885
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Abemaciclib;   Drug: Fulvestrant;   Drug: Standard Chemotherapy
    Sponsor:   Eli Lilly and Company
    Recruiting
  • A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
    NCT03972709
    Conditions:   Macular Degeneration, Age-Related;   Geographic Atrophy
    Interventions:   Drug: RO7171009;   Drug: Sham Control
    Sponsor:   Genentech, Inc.
    Recruiting
  • Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
    NCT03941483
    Condition:   Acute Kidney Injury (AKI)
    Interventions:   Drug: ASP1128;   Drug: Placebo
    Sponsor:   Astellas Pharma Inc
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC